Astrazeneca (AZNCF) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Astrazeneca (AZNCF) over the last 17 years, with Q4 2025 value amounting to -$7.9 billion.
- Astrazeneca's Enterprise Value fell 1129.05% to -$7.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.9 billion, marking a year-over-year decrease of 1129.05%. This contributed to the annual value of -$7.9 billion for FY2025, which is 1129.05% down from last year.
- As of Q4 2025, Astrazeneca's Enterprise Value stood at -$7.9 billion, which was down 1129.05% from -$10.0 billion recorded in Q3 2025.
- Astrazeneca's 5-year Enterprise Value high stood at -$5.5 billion for Q3 2022, and its period low was -$16.6 billion during Q2 2021.
- Moreover, its 5-year median value for Enterprise Value was -$7.0 billion (2022), whereas its average is -$7.8 billion.
- As far as peak fluctuations go, Astrazeneca's Enterprise Value tumbled by 33695.34% in 2021, and later skyrocketed by 6440.68% in 2022.
- Astrazeneca's Enterprise Value (Quarter) stood at -$6.4 billion in 2021, then rose by 0.11% to -$6.4 billion in 2022, then increased by 7.26% to -$5.9 billion in 2023, then fell by 19.9% to -$7.1 billion in 2024, then fell by 11.29% to -$7.9 billion in 2025.
- Its Enterprise Value was -$7.9 billion in Q4 2025, compared to -$10.0 billion in Q3 2025 and -$8.9 billion in Q2 2025.